Intellia Therapeutics Could Rise 167%, Per Wall Street, But Is It a Buy?
Wall Street analysts are quite bullish right now on gene-editing specialist Intellia Therapeutics (NASDAQ: NTLA) -- expecting, on average, the stock to soar 167% in the coming 12 months. Yet, Intellia has a very long way to go before it has a chance to commercialize any of its product candidates, and there's nothing to suggest it's on the verge of suddenly hitting the lottery and bringing in hundreds of millions in revenue.
So what are the analysts getting at with their estimates, and should you buy this stock?
Intellia's pipeline has two focuses, both of which pertain to its use of gene-editing technologies to treat or cure illnesses.
Source Fool.com
Intellia Therapeutics Inc Stock
€19.39
4.360%
Intellia Therapeutics Inc is currently one of the favorites of our community with 12 Buy predictions and no Sell predictions.
Based on the current price of 19.39 € the target price of 60 € shows a potential of 209.52% for Intellia Therapeutics Inc which would more than double the current price.
